Bruker has introduced a new nuclear magnetic resonance (NMR)-based molecular phenomics clinical research tool called PhenoRisk PACS RuO for the assessment of risk and multi-organ damage in ‘Long Covid’ patients.
The investigation-only test allows for risk screening for Post-Acute Covid Syndrome (PACS), which is commonly known as Long Covid Syndrome.
It also enables quantitative multiplex testing for the early detection of clinically well-characterized risk markers.
The tool uses a multiplexed combination of biomarkers, which were discovered at the Australian National Phenome Center (ANPC) at Murdoch University in Perth.
PhenoRisk PACS RuO is designed for early stage risk factor research, monitoring of longitudinal recovery and potential damage to secondary organs in cardiovascular disease, renal dysfunction and inflammation, and type II diabetes.
The test includes an Avance IVDr NMR spectroscopy system that can simultaneously evaluate many biological mechanisms of action in a blood test taken from Lung Covid patients.
Moreover, it characterizes the metabolic and proteomic biomarkers of SARS-CoV-2 pathobiology, even in cases of asymptomatic acute Covid.
This enables the evaluation of multi-organ risk, recovery and therapeutic research in various dysfunctions associated with Lung Covid.
By studying Covid-triggered phenoconversion, the PhenoRisk PACS RuO test can distinguish PACS patients from healthy or fully recovered individuals.
In addition, the test can measure composite signals for glycoproteins and phospholipid moieties, which help indicate inflammatory and cardiovascular disease risk, as well as a novel NMR biomarker known as Supramolecular Phospholipid Composite (SPC).
dr. Iris Mangelschots, president of the applied industrial and clinical division of Bruker BioSpin, said: “We are very pleased to offer this multi-organ PACS risk screen to the clinical and pharmaceutical research community, following preliminary validation by our partners in the International Covid-19 Research Network.
“We believe that PhenoRisk PACS RuO could make an important contribution to research to combat the effects of Lung Covid.”
Related companies
